Diabetes Mellitus, Insulin-Dependent Clinical Trial
Official title:
Subject: A Blinded Randomized Trial: the Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control
Background: Pediatric patients with type 1 diabetes mellitus are known to be a challenging
group for achieving recommended glycemic control. Coping with the demands of self-managing
IDDM in children and adolescents can be a formidable task, requiring a healthy and balanced
diet, monitoring and regular insulin injections. Most patients are non-compliant to the
treatment. A number of controlled studies have examined the efficiency of psychosocial
interventions for improving compliance and glycemic control among diabetic youth. None has
examined the effectiveness of guided imagery in treatment of type 1 diabetes mellitus.
Primary Objective: To asses simultaneously the effect of listening to auditory guided
imagery and blood glucose variability, compared to variability in blood glucose while
listening to songs.
Secondary Objective To assess the effect of routine auditory guided imagery to glycemic
control and quality of life in children with type 1 diabetes mellitus, compared to listening
listening to songs.
Methods:
Subjects: 14 youth ages 7-16 years with type 1 diabetes mellitus , for at least 6 months,
and not during the honey moon period will be recruited, and will be blindly randomized to
receive intervention (auditory guided imagery group) or control (regular auditory music).
Protocol:
Design: A randomized Controlled Blinded Study Intervention: 14 randomly numbered CD's will
be prepared at study initiation, half containing auditory guided imagery and half containing
music.
Study protocol: After an initial check up, including HbA1C levels, and explanation of study
procedures the participants will be given either the intervention or the control CD, to be
used twice a day for five days. During this period continuous glucose monitoring will be
performed. On days one and five the procedure will take place while the participants are
connected to biofeedback. QOL questionnaires will be completed at the beginning of day one,
or before.
In the second part of the study the children will use the intervention / control CD at home
twice a week for 12 weeks. At the end of the study period they will again be evaluated,
including HbA1C, and all subjects will again complete QOL questionnaires
14 participants will be assigned research numbers in a consecutive recruitment
order.(01-14).
14 auditory disks will be prepared ahead of study initiation, 7 with the guided imagery
program and 7 with regular songs.
All will look similar from the outside. The disks will be numbered 01-14. Disks numbering
will be performed by an investigator who is not part of treatment team, without knowing
which disk contains which content. So that the team and participants are blinded to the disk
content at initiation.
Children and parents will be aware of the type of auditory disk after initial auscultation
at visit number 1.
The team will continue to be blinded to type of disk until end of study. 3. All participants
will be aware at study initiation that they may receive the auditory guided imagery disk or
a regular songs / story auditory disk.
4. Visit no. 1:
1. Will be arranged on date of their regular clinic visit
2. Guidance to disk usage
3. Biofeedback for autonomic parameters assessment
4. Participants will be connected to the continuous glucose monitoring system (A system
which the patient is blinded to glucose readings).
5. Participants and parents will fill QOL questionnaire [The Diabetes Treatment
Satisfaction Questionnaire (DTSQ) by Bradley C. et Al (16)], if not filled before.
6. Participants will listen to disk for the first time in clinic, alone in a room with the
parent
7. At this stage participants will be aware of the group they are in (treatment vs.
control), but team is still unaware.
8. Participants will be able to come with brothers and parents and recreational activity
will be available at site for all for entertainment 5. Visit no. 2-5: 6. Participants
will listen to disk twice a day for the next four days alone in a room in our clinic.
They will be able to come with brothers and parents, and recreational activity will be
available at site for all for entertainment.
7. 5th day visit:
a. Participants will listen to disk for the last times in clinic, alone in a room.
b. Participants will be disconnected from CGMS c. Biofeedback for autonomic parameters
assessment 8. Participants will listen to disk at least twice a week, for additional 11
weeks, at their choice of time and day, and will record the specific time of listening on
study chart 9. Visit no. 6:
1. Will be arranged on date of their regular clinic visit (12-14 weeks after visit no. 1)
2. Biofeedback for autonomic parameters assessment
3. Participants and parents will fill QOL questionnaires (The Diabetes Treatment
Satisfaction Questionnaire (DTSQ) by Bradley C. et Al (16)
4. End of study 10. Data will be collected from charts from dates of visit no. 1 and visit
no. 3 regarding: weight, height, BMI, 14 days average blood glucose levels, HbA1c.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01322789 -
Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00035750 -
Risk Factors for Atherogenesis in Type 1 Diabetes
|
N/A | |
| Completed |
NCT00005754 -
Coronary Artery Calcification in Type 1 Diabetes
|
N/A | |
| Completed |
NCT00005474 -
Markers and Mechanisms of Macrovascular Disease in IDDM
|
N/A | |
| Completed |
NCT01236365 -
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT01216618 -
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
|
Phase 3 | |
| Completed |
NCT00071409 -
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT00069537 -
Continuous Glucose Monitors for Children With Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT05168657 -
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
|
N/A | |
| Withdrawn |
NCT00297635 -
Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy
|
Phase 2 | |
| Completed |
NCT00184821 -
Ischemic Injury and Ischemic Preconditioning in Diabetes
|
N/A | |
| Completed |
NCT00073255 -
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
| Completed |
NCT00690066 -
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
|
Phase 2 | |
| Active, not recruiting |
NCT04078308 -
Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00069628 -
Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer
|
Phase 4 | |
| Completed |
NCT00044395 -
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
|
Phase 3 | |
| Completed |
NCT00044408 -
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
|
Phase 3 | |
| Completed |
NCT00069615 -
Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children
|
Phase 4 | |
| Completed |
NCT00005539 -
Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes
|
N/A | |
| Completed |
NCT04689685 -
The RADAR Study - Wearable-Based Dysglycemia Detection and Warning in Diabetes
|